U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT07465224) titled 'A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus' on March 06.
Brief Summary: The purpose of this study is to evaluate the effect of a single dose of ALN-4324 on whole-body insulin sensitivity in participants with T2DM
Study Start Date: Jan. 15
Study Type: INTERVENTIONAL
Condition:
Type 2 Diabetes Mellitus (T2DM)
Intervention:
DRUG: ALN-4324
ALN-4324 will be administered subcutaneously (SC).
DRUG: Placebo
Placebo will be administered SC.
Recruitment Status: RECRUITING
Sponsor: Alnylam Pharmaceuticals
Published by HT Digital Content Services with permission from Health Daily Dig...